	US 11,946,078 B2
	Polypeptides with endoglucanase activity and uses thereof
Neeraj Pandey, Clapham (GB); Sina Pricelius, Leiden (NL); Annapurna Sachan, Kanpur (IN); Stepan Shipovskov, Egå (DK); Richard Bott, Kirkland, WA (US); and Ajit Kumar Satapathy, Bangalore (IN)
Assigned to Danisco US Inc., Palo Alto, CA (US)
Filed by DANISCO US INC, Palo Alto, CA (US)
Filed on Apr. 22, 2021, as Appl. No. 17/237,235.
Application 17/237,235 is a continuation of application No. 16/062,911, abandoned, previously published as PCT/US2016/067223, filed on Dec. 16, 2016.
Claims priority of provisional application 62/269,678, filed on Dec. 18, 2015.
Prior Publication US 2021/0309983 A1, Oct. 7, 2021
Int. Cl. C12N 9/24 (2006.01); C11D 3/386 (2006.01); C12N 9/42 (2006.01); C12N 15/63 (2006.01)

CPC C12N 9/2437 (2013.01) [C11D 3/38645 (2013.01); C12N 9/24 (2013.01); C12N 15/63 (2013.01); C12Y 302/01004 (2013.01)]

15 Claims

1. A cellulase variant comprising an amino acid sequence comprising a substitution of A142P, wherein said variant has endoglucanase activity, wherein said variant has an amino acid sequence having at least 91% sequence identity to SEQ ID NO: 5, and wherein the amino acid positions of the variant, are numbered by correspondence with the amino acid sequence of SEQ ID NO:5.